That's 'ALS' She Wrote: Biogen Phase III Another Bust in Space
By Randy Osborne
Thursday, January 3, 2013
With most investor eyes focused on the waited-for FDA approval of Biogen Idec Inc.'s BG-12 for early stage multiple sclerosis (MS), the market hardly flinched at news that dexpramipexole failed in a Phase III trial for amyotrophic lateral sclerosis (ALS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.